Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

105.31 +0.77 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 95,418
Open 104.00
Bid (Size) 104.90 (1)
Ask (Size) 105.31 (5)
Prev. Close 104.54
Today's Range 101.84 - 105.42
52wk Range 77.42 - 129.90
Shares Outstanding 16,676,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy
Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth. 
Via Benzinga
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga

Performance

YTD
-2.9%
-2.9%
1 Month
+0.5%
+0.5%
3 Month
-12.2%
-12.2%
6 Month
-5.7%
-5.7%
1 Year
+21.6%
+21.6%

More News

Read More
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals
Via Benzinga
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings
Via Benzinga
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated
Via Stocktwits
Dow Falls Over 1%; US Initial Jobless Claims Decline
Via Benzinga
Topics Stocks
Exposures US Equities
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
The Latest Analyst Ratings For Ligand Pharmaceuticals
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Via Investor's Business Daily
Ligand to Present at Stifel 2024 Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
From Palvella Therapeutics
Via GlobeNewswire
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire

Frequently Asked Questions

Is Ligand Pharmaceuticals Incorporated - Common Stock publicly traded?
Yes, Ligand Pharmaceuticals Incorporated - Common Stock is publicly traded.
What exchange does Ligand Pharmaceuticals Incorporated - Common Stock trade on?
Ligand Pharmaceuticals Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock?
The ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock is LGND on the Nasdaq Stock Market
What is the current price of Ligand Pharmaceuticals Incorporated - Common Stock?
The current price of Ligand Pharmaceuticals Incorporated - Common Stock is 105.31
When was Ligand Pharmaceuticals Incorporated - Common Stock last traded?
The last trade of Ligand Pharmaceuticals Incorporated - Common Stock was at 05/19/25 04:00 PM ET
What is the market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock?
The market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock is 1.76B
How many shares of Ligand Pharmaceuticals Incorporated - Common Stock are outstanding?
Ligand Pharmaceuticals Incorporated - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.